New materials and complications of prostheses in humans: situation in Spain.

M Vallet-Regí, A De Alarcón, E Gómez Barrena, J A Planell, J Silva, E Bouza
Author Information
  1. E Bouza: Emilio Bouza, Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid. Spain. emilio.bouza@gmail.com.

Abstract

Prostheses or implantable medical devices (IMDs) are parts made of natural or artificial materials intended to replace a body structure and therefore must be well tolerated by living tissues. The types of IMDs currently available and usable are very varied and capable of replacing almost any human organ. A high but imprecise percentage of Spaniards are carriers of one or more IMDs to which they often owe their quality of life or survival. IMDs are constructed with different types of materials that are often combined in the same prosthesis. These materials must combine harmlessness to human tissues with high wear resistance. Their durability depends on many factors both on the host and the type of prosthesis, but the vast majority last for more than 10-15 years or remain in function for the lifetime of the patient. The most frequently implanted IMDs are placed in the heart or great vessels, joints, dental arches or breast and their most frequent complications are classified as non-infectious, particularly loosening or intolerance, and infectious. Complications, when they occur, lead to a significant increase in morbidity, their repair or replacement multiplies the health care cost and, on occasions, can cause the death of the patient. The fight against IMD complications is currently focused on the design of new materials that are more resistant to wear and infection and the use of antimicrobial substances that are released from these materials. Their production requires multidisciplinary technical teams, but also a willingness on the part of industry and health authorities that is not often found in Spain or in most European nations. Scientific production on prostheses and IMD in Spain is estimated to be less than 2% of the world total, and probably below what corresponds to our level of socio-economic development. The future of IMDs involves, among other factors, examining the potential role of Artificial Intelligence in their design, knowledge of tissue regeneration, greater efficiency in preventing infections and taking alternative treatments beyond antimicrobials, such as phage therapy. For these and other reasons, the Ramón Areces Foundation convened a series of experts in different fields related to prostheses and IMDs who answered and discussed a series of questions previously formulated by the Scientific Council. The following lines are the written testimony of these questions and the answers to them.

Keywords

References

  1. Can Prosthet Orthot J. 2020 May 21;2(1):33640 [PMID: 37614806]
  2. Rev Esp Cardiol (Engl Ed). 2023 Dec;76(12):1021-1031 [PMID: 37863184]
  3. Front Cardiovasc Med. 2022 Oct 13;9:945726 [PMID: 36312266]
  4. J Prosthet Dent. 2023 Feb;129(2):293-300 [PMID: 34144789]
  5. Acta Biomater. 2022 Apr 15;143:1-25 [PMID: 35202854]
  6. Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6365-6381 [PMID: 36089638]
  7. Microb Drug Resist. 2011 Jun;17(2):191-6 [PMID: 21395450]
  8. Sex Med Rev. 2019 Jan;7(1):178-188 [PMID: 30503794]
  9. Heart Rhythm. 2013 Apr;10(4):e59-65 [PMID: 23403056]
  10. Mater Today Bio. 2021 Nov 23;12:100165 [PMID: 34877520]
  11. Int Orthop. 2023 Mar;47(3):873-883 [PMID: 36651984]
  12. Tech Coloproctol. 2018 Apr;22(4):265-270 [PMID: 29732505]
  13. Z Evid Fortbild Qual Gesundhwes. 2012;106(5):322-31; discussion 332 [PMID: 22818149]
  14. J Arthroplasty. 2023 Aug;38(8):1434-1437 [PMID: 36805115]
  15. Orthop Traumatol Surg Res. 2019 Jun;105(4):639-645 [PMID: 31088772]
  16. Cureus. 2023 Feb 16;15(2):e35059 [PMID: 36942167]
  17. Hernia. 2021 Oct;25(5):1129-1135 [PMID: 33555463]
  18. Orthop Rev (Pavia). 2016 Mar 31;8(1):6113 [PMID: 27114806]
  19. Arch Immunol Ther Exp (Warsz). 1987;35(5):569-83 [PMID: 3455647]
  20. Bioeng Transl Med. 2023 Jun 26;8(6):e10565 [PMID: 38023705]
  21. J Dent Res. 2018 Dec;97(13):1424-1430 [PMID: 30075090]
  22. Biomaterials. 2016 Jul;95:35-46 [PMID: 27108404]
  23. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):108-16 [PMID: 23264436]
  24. Bioengineering (Basel). 2022 Oct 17;9(10): [PMID: 36290529]
  25. Europace. 2014 Oct;16(10):1482-9 [PMID: 24919539]
  26. J Shoulder Elbow Surg. 2022 Sep;31(9):1884-1889 [PMID: 35429632]
  27. RSC Adv. 2023 Jul 10;13(30):20495-20511 [PMID: 37435384]
  28. Materials (Basel). 2020 Jul 08;13(14): [PMID: 32650529]
  29. Int J Med Robot. 2023 Sep 30;:e2582 [PMID: 37776329]
  30. J Plast Reconstr Aesthet Surg. 2016 Feb;69(2):196-205 [PMID: 26794627]
  31. PLoS One. 2016 Mar 04;11(3):e0150074 [PMID: 26943789]
  32. Rev Esp Cardiol (Engl Ed). 2022 Apr;75(4):325-333 [PMID: 34016548]
  33. Mater Today Bio. 2021 Jun 29;11:100121 [PMID: 34377972]
  34. Adv Mater. 2013 Feb 13;25(6):802-24 [PMID: 23297023]
  35. Clin Infect Dis. 2023 Nov 2;77(Suppl 5):S337-S351 [PMID: 37932122]
  36. Int Neurourol J. 2013 Sep;17(3):98-106 [PMID: 24143287]
  37. J Plast Reconstr Aesthet Surg. 2022 Jan;75(1):85-93 [PMID: 34627717]
  38. Viruses. 2023 May 20;15(5): [PMID: 37243293]
  39. Nat Rev Cardiol. 2021 Aug;18(8):600-609 [PMID: 33712806]
  40. Biomed Eng Lett. 2019 Nov 11;10(1):5-16 [PMID: 32175127]
  41. Arch Immunol Ther Exp (Warsz). 1985;33(2):241-59 [PMID: 2935116]
  42. J Am Coll Cardiol. 2016 Jan 5;67(1):29-38 [PMID: 26764063]
  43. Bioorg Chem. 2023 Jul;136:106551 [PMID: 37094480]
  44. Nat Mater. 2010 Sep;9(9):768-78 [PMID: 20729850]
  45. Clin Infect Dis. 2023 Nov 2;77(Suppl 5):S384-S394 [PMID: 37932121]
  46. N Engl J Med. 2024 Feb 1;390(5):442-454 [PMID: 38294976]
  47. Arch Immunol Ther Exp (Warsz). 1985;33(2):219-40 [PMID: 2935115]
  48. JACC Cardiovasc Interv. 2023 Oct 23;16(20):2479-2497 [PMID: 37879802]
  49. J Arthroplasty. 2024 Feb;39(2):568 [PMID: 37981530]
  50. Arch Immunol Ther Exp (Warsz). 1984;32(3):317-35 [PMID: 6395825]
  51. Front Microbiol. 2022 May 10;13:796132 [PMID: 35620093]
  52. Heart Fail Rev. 2020 May;25(3):495-503 [PMID: 31823104]
  53. Rev Esp Cardiol (Engl Ed). 2023 Dec;76(12):1032-1041 [PMID: 37852369]
  54. Sci Rep. 2023 Sep 13;13(1):15188 [PMID: 37704798]
  55. Adv Colloid Interface Sci. 2017 Dec;250:15-24 [PMID: 29129313]
  56. AAPS PharmSciTech. 2023 Sep 19;24(7):191 [PMID: 37726576]
  57. J Orthop. 2020 Dec 25;23:88-96 [PMID: 33442223]
  58. J Mater Chem B. 2022 Apr 6;10(14):2338-2356 [PMID: 35212331]
  59. Kardiol Pol. 2022;80(9):919-925 [PMID: 35698969]
  60. Orthop Surg. 2021 Apr;13(2):395-401 [PMID: 33506615]
  61. Ann Phys Rehabil Med. 2022 Nov;65(6):101635 [PMID: 35091112]
  62. J Med Econ. 2020 Jul;23(7):698-705 [PMID: 32255386]
  63. Arch Immunol Ther Exp (Warsz). 1985;33(2):261-73 [PMID: 2935117]
  64. Ann Rheum Dis. 2003 Mar;62(3):222-6 [PMID: 12594106]
  65. Clin Infect Dis. 2023 Nov 2;77(Suppl 5):S407-S415 [PMID: 37932115]
  66. J Craniofac Surg. 2010 Jan;21(1):94-6 [PMID: 20061968]
  67. Arthroplast Today. 2021 May 17;9:68-72 [PMID: 34041332]
  68. Acta Otorhinolaryngol Ital. 2024 Feb;44(1):52-67 [PMID: 38165206]
  69. Prosthet Orthot Int. 2012 Jun;36(2):145-58 [PMID: 22307861]
  70. Arch Immunol Ther Exp (Warsz). 1983;31(3):293-327 [PMID: 6651485]
  71. Medicine (Baltimore). 2015 Oct;94(43):e1816 [PMID: 26512582]
  72. J Colloid Interface Sci. 2020 Mar 15;563:92-103 [PMID: 31869588]
  73. Europace. 2018 Dec 1;20(12):1974-1980 [PMID: 29672690]
  74. J Dent. 2017 Oct;65:22-40 [PMID: 28789860]
  75. Annu Rev Med. 2017 Jan 14;68:1-13 [PMID: 27686020]
  76. Viruses. 2023 Feb 10;15(2): [PMID: 36851713]
  77. Orthop Traumatol Surg Res. 2024 Sep;110(5):103852 [PMID: 38428486]
  78. Adv Mater. 2022 Jan;34(1):e2102703 [PMID: 34617632]
  79. N Engl J Med. 2019 May 16;380(20):1895-1905 [PMID: 30883056]
  80. Ther Adv Urol. 2023 Jul 14;15:17562872231179008 [PMID: 37465318]
  81. J Clin Med. 2022 Nov 24;11(23): [PMID: 36498503]
  82. Rev Esp Cardiol (Engl Ed). 2023 Nov;76(11):922-935 [PMID: 37774946]
  83. Infect Drug Resist. 2022 May 31;15:2797-2811 [PMID: 35668859]
  84. Ann Thorac Surg. 2013 Jan;95(1):98-104 [PMID: 23063201]
  85. Antibiotics (Basel). 2020 May 21;9(5): [PMID: 32455557]
  86. Swiss Med Wkly. 2005 Apr 30;135(17-18):243-51 [PMID: 15965826]
  87. Int J Clin Pract. 2021 Feb;75(2):e13806 [PMID: 33128841]
  88. Eur J Health Econ. 2015 Nov;16(8):879-93 [PMID: 25323413]
  89. APMIS. 2017 Apr;125(4):392-417 [PMID: 28407425]
  90. Europace. 2019 Feb 01;21(2):290-297 [PMID: 30590458]
  91. Clin Microbiol Infect. 2023 Jun;29(6):710-713 [PMID: 36805835]
  92. Trends Biotechnol. 2015 Nov;33(11):637-652 [PMID: 26463723]
  93. Front Med (Lausanne). 2023 May 19;10:1199657 [PMID: 37275366]
  94. Arch Immunol Ther Exp (Warsz). 1983;31(3):267-91 [PMID: 6651484]
  95. J Shoulder Elbow Surg. 2022 Dec;31(12):2449-2456 [PMID: 36007864]
  96. Adv Mater. 2013 May 14;25(18):2542-7 [PMID: 23417823]
  97. Expert Opin Ther Pat. 2020 Dec;30(12):917-930 [PMID: 32985271]
  98. Adv Colloid Interface Sci. 2018 Nov;261:1-14 [PMID: 30376953]
  99. Int J Prosthodont. 2004 Jan-Feb;17(1):83-93 [PMID: 15008238]
  100. Acta Biomater. 2019 Jan 1;83:29-36 [PMID: 30273746]
  101. Biomaterials. 2016 Oct;104:87-103 [PMID: 27449946]
  102. Int J Prosthodont. 2006 Jul-Aug;19(4):339-48 [PMID: 16900816]
  103. Lancet Infect Dis. 2022 Aug;22(8):e208-e220 [PMID: 35248167]
  104. Acta Biomater. 2021 Aug;130:54-65 [PMID: 34087445]
  105. Prosthet Orthot Int. 2007 Jun;31(2):167-76 [PMID: 17520494]
  106. J Endovasc Ther. 2024 Feb 27;:15266028241234001 [PMID: 38410837]
  107. Curr Opin Otolaryngol Head Neck Surg. 2017 Jun;25(3):188-194 [PMID: 28277334]
  108. J Arthroplasty. 2024 Mar;39(3):760-765 [PMID: 37717833]
  109. Orthopedics. 2009 Sep;32(9): [PMID: 19751021]

MeSH Term

Humans
Spain
Prostheses and Implants
Prosthesis Failure
Prosthesis-Related Infections
Prosthesis Design
Biocompatible Materials

Chemicals

Biocompatible Materials

Word Cloud

Created with Highcharts 10.0.0IMDsmaterialsoftencomplicationshealthdesignproductionSpainprosthesesProsthesesdevicesmusttissuestypescurrentlyhumanhighdifferentprosthesiswearfactorspatientlooseningcarecostIMDinfectionScientificseriesquestionsimplantablemedicalpartsmadenaturalartificialintendedreplacebodystructurethereforewelltoleratedlivingavailableusablevariedcapablereplacingalmostorganimprecisepercentageSpaniardscarriersoneowequalitylifesurvivalconstructedcombinedcombineharmlessnessresistancedurabilitydependsmanyhosttypevastmajoritylast10-15yearsremainfunctionlifetimefrequentlyimplantedplacedheartgreatvesselsjointsdentalarchesbreastfrequentclassifiednon-infectiousparticularlyintoleranceinfectiousComplicationsoccurleadsignificantincreasemorbidityrepairreplacementmultipliesoccasionscancausedeathfightfocusednewresistantuseantimicrobialsubstancesreleasedrequiresmultidisciplinarytechnicalteamsalsowillingnesspartindustryauthoritiesfoundEuropeannationsestimatedless2%worldtotalprobablycorrespondslevelsocio-economicdevelopmentfutureinvolvesamongexaminingpotentialroleArtificialIntelligenceknowledgetissueregenerationgreaterefficiencypreventinginfectionstakingalternativetreatmentsbeyondantimicrobialsphagetherapyreasonsRamónArecesFoundationconvenedexpertsfieldsrelatedanswereddiscussedpreviouslyformulatedCouncilfollowinglineswrittentestimonyanswersthemNewhumans:situationImplantableMedicalDevicesarthroplastiesbiomaterialsendocarditisendovascularexpenditurescientific

Similar Articles

Cited By

No available data.